Effects of Inulin on Satiety and Food Intake (Inulin)

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Maastricht University Medical Center

ClinicalTrials.gov Identifier:

NCT01025375

First received: December 2, 2009

Last updated: August 29, 2012

Last verified: August 2012

History of Changes

Purpose

To assess the effect of inulin on appetite profile ratings, food intake and satiety hormones.

Condition	Intervention
Obesity	Dietary Supplement: inulin Dietary Supplement: placebo


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Participant, Investigator)
Official Title:	Effects of Inulin on Satiety and Food Intake

Resource links provided by NLM:

Drug Information available for: Inulin

U.S. FDA Resources

Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:

food intake [ Time Frame: on testday 0 and 13 ]

Secondary Outcome Measures:

appetite profile ratings [ Time Frame: on test day 0, 8 and 13 (at 16 time points) ]
satiety hormones (GLP-1 and PYY) [ Time Frame: on test day 0 and 13 (at 9 time points ]


Enrollment:	30
Study Start Date:	January 2009
Study Completion Date:	February 2010
Primary Completion Date:	February 2010 (Final data collection date for primary outcome measure)

Intervention Details:

10gram/day inulin for 13-day treatment

Other Name: oligofructose

16gram/day inulin for 13-day treatment

Other Name: oligofructose

16gram/day maltodextrin (placebo) for 13-day treatment

Other Name: maltodextrin

Detailed Description:

Based upon a slower digestion and the fermentation in the intestinal tract, food containing soluble dietary fibres, such as inulin, is hypothesized to be more satiating, and to limit energy intake, in humans. Does supplementation of inulin (at 2 dosages) versus placebo over 13 consecutive days in normal to overweight men and women, lead to an increase in satiety, a reduction in food intake and stronger postprandial increases in GLP-1 and PYY?

Eligibility


Ages Eligible for Study:	18 Years to 60 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

age between 18 and 60 years
BMI between 23 and 28 kg/m2
dietary unrestraint (TFEQ: F1<9)

Exclusion Criteria:

age under 18 and above 60 years
BMI under 23 and above 28 kg/m2
dietary restraint (TFEQ: F1>9)
use of medication
pregnant or breastfeeding

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01025375

Locations


Netherlands
Maastricht University
Maastricht, Limburg, Netherlands, 6229ER

Sponsors and Collaborators

Maastricht University Medical Center

Investigators


Principal Investigator:	Klaas R Westerterp, Prof	NUTRIM

More Information


Responsible Party:	Maastricht University Medical Center
ClinicalTrials.gov Identifier:	NCT01025375 History of Changes
Other Study ID Numbers:	HumBio_Westerterp08_2
Study First Received:	December 2, 2009
Last Updated:	August 29, 2012

Keywords provided by Maastricht University Medical Center:


overweight

ClinicalTrials.gov processed this record on June 22, 2017

To Top